Theravance Biopharma (TBPH) Tops Q1 EPS by 4c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($1.22), $0.04 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.43 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Veeva Systems (VEEV) Tops Q1 EPS by 10c, Offers Guidance
• CrowdStrike Holdings Inc. (CRWD) Tops Q1 EPS by 3c, Offers Guidance